Last updated: May 18, 2026
What kisspeptin-10 is
Kisspeptin-10 is the biologically active C-terminal decapeptide of kisspeptin-54, encoded by the KISS1 gene. Discovered in 1996 as a cancer metastasis suppressor (originally called metastin), kisspeptin’s role as a key reproductive hormone was established in the early 2000s.
Mechanism — the HPG axis trigger
Kisspeptin-10 binds GPR54 (also called KISS1R), a Gq-coupled receptor expressed on hypothalamic GnRH neurons. Receptor activation stimulates GnRH release, which cascades to:
- Pituitary LH release
- Pituitary FSH release
- Gonadal sex hormone production (testosterone, estrogen)
Kisspeptin neurons are the master regulators of the HPG axis. Loss-of-function mutations in KISS1 or KISS1R cause normosmic hypogonadotropic hypogonadism (delayed or absent puberty).
Research applications
Hypogonadism
Phase 1/2 trials show kisspeptin administration can restore LH pulsatility in men with hypogonadotropic hypogonadism. May be useful for fertility treatment in men with HH.
Polycystic ovary syndrome (PCOS)
Kisspeptin levels are altered in PCOS. Studies investigating kisspeptin antagonists or modulators for managing the hyperandrogenic phenotype.
Fertility / IVF
Kisspeptin has been investigated as a final maturation trigger for IVF, potentially replacing or supplementing hCG. May reduce ovarian hyperstimulation syndrome risk.
Anorexia and hypothalamic amenorrhea
Kisspeptin can restore reproductive function in conditions where HPG axis is suppressed by undernutrition or stress.
Research dosing
Clinical research has used:
- Intravenous bolus: 0.3-10 µg/kg (for acute LH testing)
- Subcutaneous injection: 1-10 µg/kg (for chronic stimulation studies)
Research-community protocols are not standardized; use is generally for hormonal investigation rather than chronic dosing.
Safety profile
Kisspeptin-10 has been notably well-tolerated in published clinical studies. No serious adverse events at studied doses. Theoretical concerns about long-term HPG axis stimulation include:
- Receptor desensitization with chronic high-dose use
- Disruption of natural pulsatile rhythm
- Potential effects in cancer patients (kisspeptin was originally identified as a metastasis suppressor — effects on tumors are complex and pathway-specific)
Regulatory status
- US: Sold as research peptide; not FDA-approved
- Clinical trials: Multiple Phase 1/2 trials in fertility and reproductive endocrinology, mostly UK and Europe-based
Does kisspeptin-10 increase testosterone?<br />
Indirectly, yes — by triggering LH release, which stimulates testicular testosterone production. The effect is mediated through the normal HPG axis rather than direct testicular stimulation.
How does it differ from clomid or HCG?<br />
Clomid blocks estrogen feedback at the hypothalamus (indirect LH boost). HCG mimics LH directly at the testes. Kisspeptin acts upstream of both — at the kisspeptin receptor on GnRH neurons.
Is kisspeptin used for puberty induction?<br />
Investigated for that purpose, particularly in patients with congenital hypogonadotropic hypogonadism. Not approved for routine use.
Can kisspeptin reverse age-related testosterone decline?<br />
Animal data suggests this is possible. Human data is limited. The age-related decline often involves both reduced kisspeptin signaling and reduced gonadal responsiveness, so effect may be partial.